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Edited by Jesus AvilaAbstract Aging and apolipoprotein E4 (apoE4) expression are
strong risk factors for the development of Alzheimer’s disease
(AD); however, their pathological roles remain to be clariﬁed. In
the process of AD development, the conversion of the nontoxic
amyloid -protein (A) monomer to its toxic aggregates is a
fundamental process. We previously hypothesized that A aggre-
gation is accelerated through the generation of GM1 ganglioside
(GM1)-bound A which acts as a seed for A ﬁbril formation. Here
we report that GM1 level in detergent-resistant membrane
microdomains (DRMs) of synaptosomes increased with age and
that this increase was signiﬁcantly pronounced in the apoE4-
than the apoE3-knock-in mouse brain. Furthermore, we show
that A aggregation is markedly accelerated in the presence of the
synaptosomes of the aged apoE4-knock-in mouse brain. These
observations suggest that aging and apoE4 expression cooper-
atively accelerate A aggregation in the brain through an increase
in the level of GM1 in neuronal membranes.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apolipoprotein E (apoE) allele epsilon4 is the strongest ge-
netic risk factor for the development of Alzheimer’s disease
(AD) [1–4]. Previous studies suggested that apoE isoforms
modulate aggregation [5,6], clearance [7,8] and metabolism [9]
of the amyloid b-protein (Ab), a proteinaceous component of
senile plaques, through apoE and Ab interaction. Alterna-
tively, it was also suggested that apoE isoforms inﬂuence
neurite extension [10,11], neuronal integrity [12] and antioxi-
dant ability [13].
On the basis of results obtained from studies using re-
combinant human apoE isoforms and human apoE-knock-in
mice [14], we suggested that apoE modulates lipid eﬄux from* Corresponding author. Fax: +81-562-44-6594.
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doi:10.1016/j.febslet.2004.05.037neurons [15] and cholesterol distribution in the synaptic plas-
ma membranes [16] in an isoform-dependent manner. Despite
these ﬁndings, it remains to be elucidated whether putative
apoE-isoform-dependent alterations in the metabolism and/or
distribution of lipids in neuronal membranes are associated
with AD development, particularly with the conversion of
nontoxic Ab monomer to its toxic aggregates.
Regarding the mechanism underlying Ab aggregation in the
brain, we previously hypothesized that Ab adopts an altered
conformation through its binding to GM1 ganglioside (GM1)
and that the GM1-bound Ab acts as a seed for Ab ﬁbrillo-
genesis [17]. In the present study, we investigated whether
aging and expression of diﬀerent apoE isoforms modulate the
level of GM1 in neuronal membranes, particularly in deter-
gent-resistant membrane microdomains (DRMs), and also
whether such an alteration in the level of GM1, if any, inﬂu-
ences Ab aggregation in vitro.2. Materials and methods
2.1. Animals
Three diﬀerent age groups of male homozygous epsilon3 (3/3) and
epsilon4 (4/4) knock-in mice, in which a portion of the Apoe gene was
replaced with human apoE3 or apoE4 cDNA [14], were used in this
study.
2.2. Materials
Streptavidin-horseradish peroxidase conjugate (avidin-HRP) was
purchased from Amersham Bioscience (Piscataway, NJ). Cholera toxin
B subunit-horseradish peroxidase conjugated (CTX-HRP) and methyl-
b-cyclodextrin (MbCD) were obtained from Sigma–Aldrich (St. Louis,
MO). Anti-ﬂotillin monoclonal antibody (anti-ﬂotillin-1), anti-prion
protein (PrP) antibody [PrP(C-20)] and anti-Ab monoclonal antibody
(4G8) were purchased from Transduction Laboratories (Lexington,
KY), Santa Cruz Biotechnology (Santa Cruz, CA) and Signet Labo-
ratories (Dedham, MA), respectively. Biotinylated derivative of per-
fringolysin O (BCh) was prepared as previously described [18].
Bicinchoninic acid (BCA) protein assay kit was purchased from Pierce
(Rockford, IL).
2.3. Preparation of DRMs from synaptosomes
Synaptosomes were prepared from whole brain as previously re-
ported [19]. DRMs were prepared from the synaptosomes according toblished by Elsevier B.V. All rights reserved.
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protein/ml) were homogenized in MES-buﬀer saline (MBS) containing
1% Triton X-100. The sucrose concentration of the extract was ad-
justed to 40% by the addition of 80% sucrose in MBS, and then they
were overlaid with a 5%/35% discontinuous sucrose gradient in MBS
without Triton X-100, followed by centrifugation at 39 000 rpm for 20
h in an SW41-Ti rotor (Beckman, Palo Alto, CA). After centrifuga-
tion, 1-ml fractions were harvested from the top to the bottom of the
gradient.
2.4. SDS–PAGE and gel blotting
The proteins of each fraction were separated by SDS–polyacrylamide
gel electrophoresis (SDS–PAGE), transferred onto NitroBind mem-
brane (GE Osmonics, Minnetonka, MN) and visualized using ECL
system (Amersham Bioscience). For detection of cholesterol-rich do-
main, synaptosomes were incubated with BCh [18] (5 lg/ml) in PBS
containing 1 mg/ml BSA at 25 C for 20 min, and washed twice with the
same volume of PBS to remove unbound BCh. The precipitates were
subjected to fractionation for DRMs. The same volume of each fraction
was analyzed by SDS–PAGE. BCh in the gels was transferred onto
NitroBind membrane and was detected with avidin-HRP. Quantitative
scanning of the blots were performed using NIH Image version 1.59.
2.5. MbCD treatment
The synaptosomes were washed with Tris-buﬀered saline (TBS1; 20
mM Tris–HCl, 150 mMNaCl, pH 7.4) at 4 C and then resuspended in
TBS1 with or without 10 mMMbCD. After incubation at 37 C for 30
min, the mixture was centrifuged at 17 000 g for 15 min. The resul-
tant precipitates were subjected to fractionation for DRMs.
2.6. Ab incubation in the presence of synaptosomes
Seed-free solutions of Ab (Ab1–40) (Peptide Inst., Osaka, Japan)
were prepared essentially according to a previous report [21]. Ab so-
lutions at 50 lM in Tris-buﬀered saline (TBS2: 150 mM NaCl and 10
mM Tris–HCl, pH 7.4) were incubated at 37 C with or without
synaptosomes. Thioﬂavin T (ThT) ﬂuorescence intensities in the mix-
ture incubated for 24 h were determined as previously described [21].3. Results
3.1. GM1 levels in DRMs of synaptosomes
We isolated DRMs from synaptosomes prepared from three
diﬀerent age groups (8 weeks, 1 and 2 years) of apoE3- and
apoE4-knock-in mice. To determine the levels of GM1 in
DRMs, we incubated the blots of these fractions with CTX-Fig. 1. CTX binding to the blots of DRM fractions isolated from brain
synaptosomes from three diﬀerent age groups of apoE3- and apoE4-
knock-in mice. Each lane contains 0.1 lg protein of DRM fraction
isolated from synaptosomes prepared from ﬁve brains combined. The
blots were reacted with CTX-HRP. The intensities of the bands rela-
tive to those for 8 weeks old mice are indicated. Each column repre-
sents the average value 1S.D. of three values **P < 0:0001,
*P < 0:001 (one-way ANOVA combined with Sheﬀe’s test).HRP. The levels of CTX, a highly speciﬁc and sensitive for
GM1 ganglioside [22], bound to DRMs isolated from apoE4-
knock-in mouse brain synaptosomes markedly increased with
age (Fig. 1). The age-dependent increase in the level of CTX
binding to DRMs was also observed on the blots of apoE3-
knock-in mouse brain synaptosomes; however, it was not as
marked as in that of apoE4-knock-in mice (Fig. 1). To explore
the nature of age-dependent increase in CTX-binding to
DRMs, we performed further experiments using apoE4-
knock-in mouse brains.
3.2. Characterization of age-dependent GM1 accumulation in
DRMs
The levels of CTX bound to the DRM fraction (fraction 5)
markedly increased with age whereas those bound to otherFig. 2. Properties of the DRMs isolated from brain synaptosomes from
three diﬀerent age groups of apoE4-knock-in mice. (A) CTX binding
to the blots containing all sucrose density gradient fractions of syn-
aptosomes. (B) Binding of CTX, anti-ﬂotillin-1 and PrP(C-20) to the
blots of DRM fractions. To examine the levels of BCh bound to
DRMs, synaptosomes were incubated with BCh prior to fractionation.
The blots of BCh-labeled fractions were incubated with avidin-HRP.
The intensities of the bands relative to those for 8 weeks old mice are
indicated. Each column represents the average value 1S.D. of four
values. *P < 0:001 (one-way ANOVA combined with Sheﬀe’s test).
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changed with age (Fig. 2A).
To investigate whether the number or size of DRMs in-
creases with age, we incubated the synaptosomes with BCh,
which speciﬁcally binds to cholesterol-rich microdomains such
as lipid rafts [18], prior to the fractionation. We also per-
formed Western blotting of DRM fractions with antibodies
speciﬁc to ﬂotillin or PrP, which are selectively localized in
DRMs [23,24]. Notably, there was no apparent age-dependent
increase in the levels of BCh, anti-ﬂotillin-1 and PrP(C-20)
bound to the DRM fractions (Fig. 2B). These results suggest
that the age-dependent GM1 accumulation was not due to an
increase in the number or size of DRMs.
To further characterize the GM1 accumulation in DRMs,
we treated the synaptosomes with MbCD, which can potently
break down cholesterol-rich DRMs by removing cholesterol,
prior to fractionation. Following MbCD treatment, the levels
of BCh binding markedly decreased in all the fractions
(Fig. 3A). However, the levels of CTX bound to the DRM
fraction were essentially unchanged following the MbCDFig. 3. MbCD treatment of synaptosomes prepared from three diﬀerent age gr
sucrose density gradient fractions, probed with avidin-HRP. BCh-labeling wa
fractions, probed with CTX-HRP. (B) The levels of cholesterol and phosph
Tokyo, Japan) and Phospholipids C (Wako, Osaka, Japan), respectively. (C
protein assay kit. Open, shaded and closed symbols indicate the values of 8 we
values without and with MbCD treatment of synaptosomes, respectively.treatment (Fig. 3A). The levels of cholesterol in all the frac-
tions markedly decreased to below detection limits following
the MbCD treatment (Fig. 3B). Interestingly, a population of
phospholipids was still recovered in the DRM fraction
(Fig. 3B). The total protein levels in each fraction were es-
sentially unchanged following the MbCD treatment (Fig. 3C).
Taken together, these results suggest that GM1 accumulates in
a distinct subset of DRMs, which is diﬀerent from MbCD-
sensitive DRMs.
3.3. Ab aggregation in the presence of synaptosomes of apoE4
mouse brain
Finally, we investigated whether GM1 accumulation in the
DRMs of synaptosomes can potently accelerate Ab aggrega-
tion. We incubated soluble Ab1–40 in the presence of the
synaptosomes. The ﬂuorescence intensity of ThT, which spe-
ciﬁcally recognizes the amyloid structure, in the incubation
mixtures signiﬁcantly increased with age of the mice (Fig. 4A).
We performed Western blotting of both the precipitates and
supernatants of the incubation mixtures following ultracen-oups of apoE4-knock-in mice. (A) Left panel: The blots of BCh-labeled
s performed as described in the Fig. 2 legend. Right panel: The blots of
olipids in each fraction were determined using Determiner L (Kyowa,
) The total protein levels in each fraction were determined using BCA
eks, 1 and 2 years old mice, respectively. Circle and square indicate the
Fig. 4. Ab aggregation in the presence of synaptosomes prepared from
brains of three diﬀerent age groups of apoE4-knock-in mice. Ab so-
lutions were incubated at 50 lM and 37 C for 24 h in the presence or
absence of the synaptosomes. (A) ThT ﬂuorescence intensity in the
incubation mixtures of synaptosomes with or without Ab. Each col-
umn represents the average 1S.D. of four values. (B) Western blots
of the precipitates (ppt) and supernatants (sup) of the incubation
mixtures. The materials precipitated from 100 ll of incubation mixture
were subjected to SDS–PAGE following solubilization in formic acid.
The Ab in the supernatant was subjected to SDS–PAGE following
dilution with 200-fold volume of incubation buﬀer. The blots were
reacted with 4G8. The intensities of the bands relative to those for 8
wks old mice are indicated. Each column represents the aver-
age 1S.D. of three values. **P < 0:0001, *P < 0:05 (one-way AN-
OVA combined with Sheﬀe’s test).
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the levels of Ab immunoreactivities in the precipitates, and a
concomitant decrease in those in the supernatants were ob-
served with age of the mice (Fig. 4B).4. Discussion
In the present study, we suggest that aging and apoE4 ex-
pression cooperatively accelerate Ab aggregation in the brain
through an increase in the level of GM1 in particular micr-
odomains of neuronal membranes. Fagan et al. have recently
reported that Ab is accumulated in detergent-insoluble glyco-
lipid-enriched membrane domains (DIGs), corresponding to
DRMs, in the brain of amyloid precursor protein (APP)
transgenic mice expressing human apoE isoforms [25]. Taken
together with previous reports of preferential Ab accumulation
in DIGs in vivo [26–29], it seems likely that Ab accumulationin these microdomains is an early event of the process of AD
development. Although further studies are required, the results
of previous [17,30,31] and present studies suggest that GM1-
bound Ab, an endogenous seed for Ab ﬁbrillogenesis, is gen-
erated in these microdomains.
Regarding biochemical features of membrane microdo-
mains, including lipid rafts and caveolae, evidence has been
accumulating to suggest that these microdomains are heter-
ogenous [32–34]; there is a subset of microdomains that are
rich in gangliosides with low levels of cholesterol [32]. Our
results suggest that GM1 accumulates in unique microdomains
in an aging- and apoE-expression-dependent manner.
At present, it remains to be elucidated how GM1 accumu-
lates in such microdomains in aging- and apoE4-expression-
dependent manner. We previously found that cholesterol level
in the exofacial leaﬂet of synaptic plasma membranes increases
with age [19] and by apoE expression [16,35]. We also reported
that the accumulation of cholesterol in membranes can induce
the GM1 clustering [36]. Thus, one of the possible explanations
is that aging and apoE4 expression stabilize GM1 in the par-
ticular membrane microdomains. An alternative explanation
may be that both aging and apoE4 expression directly mod-
ulate traﬃcking of GM1 so that GM1 level in a subset of
microdomains increases.
In conclusion, our results suggest that one of the patholog-
ical roles of aging and apoE4 expression is acceleration of Ab
aggregation through modulation of GM1 distribution in neu-
ronal membranes.
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